Article

This study examined the association between cardiometabolic diseases (MI, stroke, and diabetes) and all-cause mortality in 2 million patients. Results showed that having all three conditions increased the risk of mortality, but this excess risk was not significantly greater than expected from the individual diseases. The presence of other comorbidities also contributed to the excess mortality risks associated with cardiometabolic disease multimorbidity.

The research highlights the increased severity of COVID-19 in patients with diabetes mellitus, noting that hyperglycaemia may worsen outcomes by affecting immune responses. It suggests that insulin should be the primary treatment for managing acute glycaemia in these patients, while the effects of glucose-lowering medications like DPP4 inhibitors and SGLT2 inhibitors remain uncertain. Further investigation into the management of diabetes in the context of COVID-19 is needed.